Alternative Bacteriophage Display Systems

Castagnoli, Luisa; Zucconi, Adriana; Quondam, Michele; Rossi, Mario; Vaccaro, Paola; Panni, Simona; Paoluzi, Serena; Santonico, Elena; Dente, Luciana; Cesareni, Gianni

doi:10.2174/1386207013331174

Cited by 49 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The bacteriophage display and cloning system using T7, T4 and λ phage was introduced in 1990s, and has several advantageous features over other phage display systems [62][63][64]. As a lytic phage, the T7 phage contains a linear double-stranded DNA genome.…”

Section: T7 Bacteriophage Systemmentioning

confidence: 99%

The Development of Single Domain Antibodies for Diagnostic and Therapeutic Applications

Leow¹,

Cheng²,

Fischer³

et al. 2018

Antibody Engineering

View full text Add to dashboard Cite

Monoclonal antibodies have become increasingly accepted as diagnostics and therapeutics for various human diseases due to their high affinity and specificity. However, several practical drawbacks are apparent for the reagents based on conventional IgG antibodies. With the emergence of antibody engineering, many problems were overcome when the recombinant antibody fragments such as Fabs, scFvs, diabodies and single domain antibodies (sdAbs), are developed. These fragments not only retain the specificity of the whole monoclonal antibodies, but are also easy to express and produce in prokaryotic expression systems. Rather unexpectedly, the natural sdAbs namely V HH s, V NAR s and variable lymphocyte receptors (VLRs) that comprise excellent biological activities were recently discovered in camelids, cartilaginous fish and lampreys, respectively. Due to their unique characteristics, including small size, high thermostability, stable folding in the nucleus and cytosol and long CDR3 regions which have access to cavities or clefts on the surface of proteins, these new binders are now investigated extensively as a substitute for conventional antibodies. This review describes the potential of sdAbs selected using in vitro display systems and their use in multiple applications.(polyclonal Abs) are heterogeneous antibody mixtures that are derived from multiple plasma cell lines. Because polyclonal antibodies comprise a mixture of different antibodies carrying numerous paratopes, they have excellent properties for recognizing antigens [2]. A monoclonal antibody (mAb) is a homogeneous antibody generated from a single B lymphocyte clone. Antibodies produced in mAb format have an extremely high specificity against a single epitope on antigens [3]. Recombinant antibodies (rAbs) are antibodies generated using molecular biology techniques. They are aimed to improve the sensitivity, selectivity, stability and immobilization properties in diagnostic applications, for example, in biosensors [4]. In making decision to use or generate polyclonal, monoclonal or recombinant antibodies, several factors should be considered, including commercial availability, possibility to raise animals, types of applications, time length of a project and costs [1]. Although a vast number of rAbs has been proposed [5][6][7][8], the natural sdAb fragments that were recently discovered from camelids (V HH s), sharks (V NAR s) and lampreys (VLRs) have shown to possess extraordinary features that are not found in conventional antibodies, such as a small dimension, an elevated stability and the capability of recognizing cavities and clefts on the surface of proteins that cannot be reached by conventional recombinant antibodies [9][10][11]. This chapter will discuss the availability of new binders derived from vertebrates and give an overview of their applications in a biomedical platform by recognizing specified targets from various diseases. Monoclonal antibodies and their limitationsThe first description of monoclonal antibody (mAbs) production was published ...

show abstract

Section: T7 Bacteriophage Systemmentioning

confidence: 99%

The Development of Single Domain Antibodies for Diagnostic and Therapeutic Applications

Leow¹,

Cheng²,

Fischer³

et al. 2018

Antibody Engineering

View full text Add to dashboard Cite

show abstract

“…to display full-length antigens from human immunodeficiency virus (HIV) (Li et al 2007 ; Shivachandra et al 2006 ). In vivo systems have been used on other phages such as λ or T7 phage (Castagnoli et al 2001 ; Maruyama et al 1994 ; Mikawa et al 1996 ). One of the limitations of in vivo display is the fact that no control can be exerted on intracellular expression structure and assembly on foreign proteins.…”

Section: Phage Displaymentioning

confidence: 99%

Molecular and Chemical Engineering of Bacteriophages for Potential Medical Applications

Hodyra

Dąbrowska

2014

Arch. Immunol. Ther. Exp.

View full text Add to dashboard Cite

Recent progress in molecular engineering has contributed to the great progress of medicine. However, there are still difficult problems constituting a challenge for molecular biology and biotechnology, e.g. new generation of anticancer agents, alternative biosensors or vaccines. As a biotechnological tool, bacteriophages (phages) offer a promising alternative to traditional approaches. They can be applied as anticancer agents, novel platforms in vaccine design, or as target carriers in drug discovery. Phages also offer solutions for modern cell imaging, biosensor construction or food pathogen detection. Here we present a review of bacteriophage research as a dynamically developing field with promising prospects for further development of medicine and biotechnology.

show abstract

“…Some displayed peptides may not be able to cross the lipid bilayer of the inner membrane. Therefore, lytic bacteriophages have been used which assemble in the cytoplasm and are released through cell lysis so that the correct transfer of the hybrid capsid protein is guaranteed [20].…”

Section: Display Systemsmentioning

confidence: 99%

Mechanistic and high-throughput approaches for the design of molecular imaging probes and targeted therapeutics

Haberkorn

Mier

Dimitrakopoulou-Strauß

et al. 2014

Clin Transl Imaging

View full text Add to dashboard Cite

Recent advances in molecular biology and biotechnology have opened the way for the development of new imaging and treatment modalities based on the biological properties of tissues. In oncology, the major advances have been achieved using peptide and antibody targeting molecules. This approach is based on: (1) the identification of new target structures, and (2) the application of new techniques for the development of new biocompatible molecules. These techniques rely on the identification of lead compounds followed by the screening of various derivatives of these compounds. For this purpose, high-throughput methods have been applied that generate a vast library of possible binders which can be used to screen the whole population for the few variants that show the property of interest. An attractive feature of this strategy is the huge number of candidate molecules that can be used for further evaluation, which consists of the characterization of structure-function relationships and the further improvement by rational design of corresponding analogs.

show abstract

Alternative Bacteriophage Display Systems

Cited by 49 publications

References 0 publications

The Development of Single Domain Antibodies for Diagnostic and Therapeutic Applications

The Development of Single Domain Antibodies for Diagnostic and Therapeutic Applications

Molecular and Chemical Engineering of Bacteriophages for Potential Medical Applications

Mechanistic and high-throughput approaches for the design of molecular imaging probes and targeted therapeutics

Contact Info

Product

Resources

About